CS-121 / CorrectSequence Therap - LARVOL DELTA

...CorrectSequence Therapeutics…announced that the first patient in its Investigator-Initiated Trial (IIT) of the base-editing therapy CS-121 targeting APOC3 for chylomicronemia / hypertriglyceridemia has successfully completed dosing and been discharged from the hospital (PRNewswire) - "The patient, diagnosed with chylomicronemia, had a long history of fasting triglyceride (TG) levels exceeding 12.5 mmol/L and recurrent acute pancreatitis. In the dose-escalation IIT for CS-121, his fasting TG level dropped significantly within three days after a single low-dose administration, with no adverse events."

Trial status • Familial Chylomicronemia Syndrome

CS-121 APOC3 Base Editing in FCS (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: CorrectSequence Therapeutics Co., Ltd

New P1 trial • Familial Chylomicronemia Syndrome